Thomson Reuters and Linguamatics Release New Solution to Advance Pharma Clinical Trial R&D

Cortellis Informatics Clinical Text Analytics for I2E uses the combination of Linguamatics’ powerful, market-leading NLP text analytics platform with the largest breadth and depth of integrated clinical content available. Through a single interface, users will be able to glean new insights in support of trials, site selection and competitive intelligence, helping them to design more effective clinical trials and gain a deeper understanding of the implications of their results.

“We are excited about this innovative project with Thomson Reuters” said John Brimacombe, executive chairman of Linguamatics. “Combining the strength of our best of breed text analytics with the wealth of content within Cortellis will be a significant step forward for our clients in advancing productivity and efficacy in pharmaceutical R&D.”

Key features include:

• Authoritative, Hand-Curated Content: Users will be able to gain greater insights from their data with the combination of state-of-the-art text and high quality, hand curated content offered by Cortellis Informatics Clinical Text Analytics for I2E.

• Access to Numeric Information: Advanced Text Analytics will allow for rapid extraction and connection of relevant facts and relationships within the content, improving speed to insight.

• Data-Driven Clinical Insights: The ability to generate data tables from these resources will support users in preclinical studies, trial design, business intelligence, and provide a deeper understanding of the impact of clinical trials.

• Streamlines Search Functionality: Fast, easy-to-use functionality allows for timely and accurate searches.

“We are pleased to be working with Linguamatics to provide the pharmaceutical industry with a solution that leverages the leading capabilities of both organizations and will provide our mutual customers with a stronger view into the clinical trial process,” said Jon Brett-Harris, managing director of Thomson Reuters Life Science business. “Our joint solution will make it easier for researchers to obtain the insights they need to help them make decisions that optimize the drug development process.”

About Linguamatics

About Thomson Reuters

Thomson Reuters is the world’s leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world’s most trusted news organization. For more information, go to www.thomsonreuters.com.